title: The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer.
abstract: OBJECTIVE
  This study investigated the differences in clinical outcomes between patients with bifurcation lesions (BL) treated with a biolimus-eluting stent (BES) with a biodegradable polymer, and a sirolimus-eluting stent (SES) with a durable polymer.
  
  
  RESULTS
  The clinical outcomes were assessed in the 497 patients (BES 258, SES 239) enrolled in the multicentre, randomised LEADERS trial who underwent treatment of ≥1 BL (total=534 BL). At 12-months follow-up there was no significant difference in the primary endpoint of MACE, a composite of cardiac death, myocardial infarction and clinically indicated target vessel revascularisation (BES 12.8% vs. SES 16.3%, p=0.31). Patients treated with BES had comparable rates of cardiac death (BES 2.7% vs. SES 2.9%, p=1.00), numerically higher rates of myocardial infarction (BES 8.9% vs. SES 5.4%, p=0.17), and significantly lower rates of clinically indicated target vessel revascularisation (4.3% vs. 11.3%, p=0.004) when compared to those treated with SES. The rate of stent thrombosis at 12-months was 4.3% and 3.8% for BES and SES, respectively (p=0.82).
  
  
  CONCLUSIONS
  In the treatment of BL the use of BES lead to superior efficacy and comparable safety compared to SES.
authors.affiliation: Department of Interventional Cardiology, Erasmus MC, Rotterdam, The Netherlands.
authors.forename: Scot
authors.initials: S
authors.lastname: Garg
authors.forename: Joanna
authors.initials: J
authors.lastname: Wykrzykowska
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Ton
authors.initials: T
authors.lastname: de Vries
authors.forename: Pawel
authors.initials: P
authors.lastname: Buszman
authors.forename: Stanislaw
authors.initials: S
authors.lastname: Trznadel
authors.forename: Axel
authors.initials: A
authors.lastname: Linke
authors.forename: Karsten
authors.initials: K
authors.lastname: Lenk
authors.forename: Thomas
authors.initials: T
authors.lastname: Ischinger
authors.forename: Volker
authors.initials: V
authors.lastname: Klauss
authors.forename: Franz
authors.initials: F
authors.lastname: Eberli
authors.forename: Roberto
authors.initials: R
authors.lastname: Corti
authors.forename: William
authors.initials: W
authors.lastname: Wijns
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Morice
authors.forename: Carlo
authors.initials: C
authors.lastname: di Mario
authors.forename: Pawel
authors.initials: P
authors.lastname: Tyczynski
authors.forename: Robert Jan
authors.initials: RJ
authors.lastname: van Geuns
authors.forename: Pedro
authors.initials: P
authors.lastname: Eerdmans
authors.forename: Gerrit-Anne
authors.initials: GA
authors.lastname: van Es
authors.forename: Bernhard
authors.initials: B
authors.lastname: Meier
authors.forename: Peter
authors.initials: P
authors.lastname: Jüni
authors.forename: Stephan
authors.initials: S
authors.lastname: Windecker
mesh_terms: D020341:Absorbable Implants / Q000009:adverse effects; D054058:Acute Coronary Syndrome / Q000401:mortality / Q000628:therapy; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000401:mortality; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy; D011108:Polymers / Q000009:adverse effects; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011108:Polymers; C518022:umirolimus; D020123:Sirolimus